VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

I am certainly not an expert, but it was my understanding that before designing a trial dosing and the longevity of a trial would be well thought out. That is not to say companies always get the study design correct. As we have seen with Allergan they changed the trial design that got them to phase 3 only to have endpoints not reached.

With AV101 I thought that the company felt with AV-101s MOA, as an NMDA antagonist, two weeks should be plenty to see a benefit. I would imagine 2 weeks was the dosing duration was supported by testing.

If Elevate is a success I would think more studies with different dosing and combinations will be tried.